Solstice Neurosciences Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $35.7M
Latest Deal Amount

Solstice Neurosciences General Information

Description

Owner and operator of a biopharmaceutical company. The company engages in the development, manufacture, marketing, and sale of biopharmaceutical products. Its products include Myobloc/NeuroBloc, a botulinum toxin type B injectable solution for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and pain associated with cervical dystonia. It also offers reimbursement support, product support, and medical information access services, as well as operates a MYOBLOC University, an online, self-study resource that incorporates learning technology for physicians.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
  • 4010 Dupont Circle
  • Suite L-07
  • Louisville, KY 40207
  • United States
+1 (502) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Solstice Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 06-Aug-2010 $35.7M 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 08-Nov-2006 0000 0000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jul-2005 $8M $8M 000.00 Completed Product Development
To view Solstice Neurosciences’s complete valuation and funding history, request access »

Solstice Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00 00.0 00 00 00.00
To view Solstice Neurosciences’s complete cap table history, request access »

Solstice Neurosciences Patents

Solstice Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100112005-A1 Compositions of activated botulinum toxin type b Abandoned 03-Nov-2008 000000000 0
US-20100112006-A1 Compositions of activated botulinum holotoxin type b (150 kd) Abandoned 03-Nov-2008 0000000000 0
US-20100034854-A1 Compositions of activated botulinum holotoxin type b (150 kd) Abandoned 05-Aug-2008 000000000 00
US-20120238504-A1 Stable formulations of botulinum toxin in hydrogels Abandoned 11-Sep-1998 00000000000 00
JP-2013144691-A Stable liquid formulation of botulinum toxin Withdrawn 11-Sep-1998 A61K9/0019

Solstice Neurosciences Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Highland Capital Management Hedge Fund Minority 000 0000 000000 0
Morgan Stanley Expansion Capital Growth/Expansion Minority 000 0000 000000 0
Oxford Bioscience Partners Venture Capital Minority 000 0000 000000 0
Patricia Industries PE/Buyout Minority 000 0000 000000 0
Thomas McNerney & Partners Venture Capital Minority 000 0000 000000 0
To view Solstice Neurosciences’s complete investors history, request access »